Remdesivir

Remdesivir showed the greatest clinical benefit in patients on nasal-cannula oxygen, with minimal benefit in patients already on mechanical ventilation. Remdesivir received emergency FDA authorization based on a trial stopped early after demonstrating a recovery benefit and a trend toward mortality benefit. Remdesivir is contraindicated in patients with significant renal impairment or elevated liver function tests. Remdesivir is available only as an intravenous formulation, making outpatient treatment logistically impractical. Access to remdesivir was constrained by supply rationing rather than insurance decisions, with treatment reserved for patients already requiring supplemental oxygen.